Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China
NCT00342472 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81
Last updated 2020-12-11
Summary
The overall goal of this project is to determine whether polycyclic aromatic hydrocarbons (PAHs) are contributing to the high rate of esophageal cancer in Linxian, China.
Esophageal cancer is one of the most fatal cancers worldwide with Linxian, China having one of the highest rates in the world. In the United States esophageal cancer causes approximately 10,000 deaths each year. It is the fourth most common cause of cancer death in black males and the eighth leading cause of cancer death in men of all races. Although several recent studies have identified some of the molecular changes associated with esophageal cancer, its prevention and treatment within high risk groups continues to be limited by our inability to identify specific etiologic agents.
Human exposure to PAHs, including benzo \[a\]pyrene (B\[a\]P), is associated with an increased rate of skin, lung, and upper GI tumors and also with an increased mortality from causes related to atherosclerosis. Evidence, including the preliminary results from histologic and food analysis pilot studies, supports the idea that this region's high rate of esophageal cancer may be related to long-term, high-level exposure to PAHs via inhalation of air-borne pollution and ingestion of food cooked with soft coal.
Thus, to assess the association of PAHs with the high rate of esophageal cancer in Linxian, China, we plan to analyze samples of food for the presence of PAHs, samples of blood for Hb adducts (a marker of long-term PAH exposure), samples of urine for 1-OH-Pyrene glucuronide (a maker of short-term PAH exposure), and samples of coal for characteristics that may be associated with increased carcinogenesis. We will also administer environmental questionnaires that will include questions about the type of fuel used for cooking and heating, the location and type of stove and/or heating unit (i.e., vented versus unvented), and time spent cooking.
Conditions
- Esophageal Cancer
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Sanford M Dawsey, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-02-12
- Primary Completion
- 2020-01-01
- Completion
- 2020-06-05
Countries
- China
Study Locations
More Related Trials
-
Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma
NCT01240369 ·Status: UNKNOWN
-
CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer
NCT03916367 ·Status: COMPLETED
-
Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors
NCT03272971 ·Status: TERMINATED ·Phase: NA
-
A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women
NCT00342004 ·Status: COMPLETED
-
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer
NCT01452971 ·Status: UNKNOWN
-
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
NCT03433924 ·Status: COMPLETED
-
Brain Neoplasms, Leukemia and Petrochemical Exposures
NCT00042445 ·Status: COMPLETED
-
Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)
NCT01778920 ·Status: COMPLETED ·Phase: PHASE1
-
Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy
NCT07257471 ·Status: RECRUITING
-
Exhaled Breath Particles in Lung Cancer
NCT05395611 ·Status: UNKNOWN
-
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
NCT06358222 ·Status: RECRUITING
-
Predictive Value of Air Pollution and Metabolomics for Gastric Cancer.
NCT06641700 ·Status: ACTIVE_NOT_RECRUITING
-
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
NCT01325753 ·Status: WITHDRAWN ·Phase: NA
-
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
NCT05834413 ·Status: RECRUITING ·Phase: NA
-
Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging
NCT01653002 ·Status: COMPLETED
-
Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
NCT06503744 ·Status: RECRUITING ·Phase: NA
-
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
NCT00303901 ·Status: COMPLETED ·Phase: NA
-
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
NCT06017271 ·Status: WITHDRAWN
-
Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma
NCT02951897 ·Status: UNKNOWN ·Phase: NA
-
Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer
NCT02701231 ·Status: UNKNOWN ·Phase: NA
-
Epidemiological Study to Assess the Prevalence of Lung Cancer
NCT03976804 ·Status: UNKNOWN ·Phase: NA
-
Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
NCT05988970 ·Status: COMPLETED ·Phase: NA
-
Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma
NCT06104709 ·Status: NOT_YET_RECRUITING
-
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540 ·Status: RECRUITING ·Phase: NA
-
Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).
NCT03634826 ·Status: UNKNOWN